Literature DB >> 24809317

Assessment of tumor grade and angiogenesis in colorectal cancer: whole-volume perfusion CT.

Hongliang Sun1, Yanyan Xu1, Qiang Yang2, Wu Wang3.   

Abstract

RATIONALE AND
OBJECTIVES: The preoperative evaluation of tumor grading and angiogenesis has important clinical implications in the treatment and prognosis of patients with colorectal cancers (CRCs). The aim of the present study was to assess tumor perfusion with 256-slice computed tomography (CT) using whole-volume perfusion technology before surgery, and to investigate the differences in the perfusion parameters among tumor grades and the correlation between perfusion parameters and pathologic results in CRC.
MATERIALS AND METHODS: Thirty-seven patients with CRC confirmed by endoscopic pathology underwent whole-volume perfusion CT assessments with a 256-slice CT and surgery. Quantitative values for blood flow, blood volume, and time to peak were determined using commercial software. After surgery, resected specimens were analyzed immunohistochemically with CD105 antibodies for the quantification of microvessel density (MVD). The difference in CT perfusion parameters and MVD among different tumor differentiation grades was evaluated by the Student-Newman-Keuls test. The correlations between CT perfusion parameters and MVD were evaluated using the Pearson correlation analysis.
RESULTS: The mean blood flow was significantly different among well, moderately, and poorly differentiated groups (61.17 ± 17.97, 34.80 ± 13.06, and 22.24 ± 9.31 mL/minute/100 g, respectively; P < .05). The blood volume in the well-differentiated group was significantly higher than that in the moderately differentiated group (33.96 ± 24.81 vs. 16.93 ± 5.73 mL/100 g; P = .002) and that in the poorly differentiated group (33.96 ± 24.81 vs. 18.05 ± 6.01 mL/100 g; P = .009). The time to peak in the poorly differentiated group was significantly longer than that in the well-differentiated group (27.81 ± 11.95 vs. 17.60 ± 8.53 seconds; P = .016) and that in the moderately differentiated group (27.81 ± 11.95 vs. 18.94 ± 7.47 seconds; P = .028). There was no significant difference in the MVD among well, moderately, and poorly differentiated groups (33.47 ± 14.69, 28.89 ± 11.82, and 29.89 ± 11.02, respectively; P > .05). There was no significant correlation between CT perfusion parameters and MVD (r = 0.201, 0.295, and -0.178, respectively; P = .233, .076, and .292, respectively).
CONCLUSIONS: CT whole-volume perfusion technology has the potential to evaluate pathologic differentiation grade of CRC before surgery. However, preoperative perfusion CT parameters do not reflect the MVD of CRC.
Copyright © 2014 AUR. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CT; Colorectal cancer; angiogenesis; perfusion

Mesh:

Substances:

Year:  2014        PMID: 24809317     DOI: 10.1016/j.acra.2014.02.011

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  9 in total

1.  Silencing of VEGF inhibits human osteosarcoma angiogenesis and promotes cell apoptosis via VEGF/PI3K/AKT signaling pathway.

Authors:  Ningning Peng; Shuming Gao; Xu Guo; Guangya Wang; Cai Cheng; Min Li; Kehun Liu
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

2.  Unenhanced areas revealed by contrast-enhanced abdominal ultrasonography with Sonazoid™ potentially correspond to colorectal cancer.

Authors:  Minoru Tomizawa; Mizuki Togashi; Fuminobu Shinozaki; Rumiko Hasegawa; Yoshinori Shirai; Midori Noritake; Yukie Matsuoka; Hiroaki Kainuma; Yasuji Iwasaki; Kazunori Fugo; Yasufumi Motoyoshi; Takao Sugiyama; Shigenori Yamamoto; Takashi Kishimoto; Naoki Ishige
Journal:  Exp Ther Med       Date:  2016-11-03       Impact factor: 2.447

3.  T staging with functional and radiomics parameters of computed tomography in colorectal cancer patients.

Authors:  Yafang Dou; Yingying Liu; Xiancheng Kong; Shangying Yang
Journal:  Medicine (Baltimore)       Date:  2022-05-27       Impact factor: 1.817

Review 4.  Colorectal cancer: Parametric evaluation of morphological, functional and molecular tomographic imaging.

Authors:  Pier Paolo Mainenti; Arnaldo Stanzione; Salvatore Guarino; Valeria Romeo; Lorenzo Ugga; Federica Romano; Giovanni Storto; Simone Maurea; Arturo Brunetti
Journal:  World J Gastroenterol       Date:  2019-09-21       Impact factor: 5.742

5.  Does perfusion computed tomography correlate to pathology in colorectal liver metastases?

Authors:  M J van Amerongen; A M Vos; W van der Woude; I D Nagtegaal; J H W de Wilt; J J Fütterer; J J Hermans
Journal:  PLoS One       Date:  2021-01-26       Impact factor: 3.240

Review 6.  A Systematic Review on the Role of the Perfusion Computed Tomography in Abdominal Cancer.

Authors:  Nunzia Garbino; Valentina Brancato; Marco Salvatore; Carlo Cavaliere
Journal:  Dose Response       Date:  2021-11-24       Impact factor: 2.658

Review 7.  Advanced imaging of colorectal cancer: From anatomy to molecular imaging.

Authors:  Roberto García-Figueiras; Sandra Baleato-González; Anwar R Padhani; Ana Marhuenda; Antonio Luna; Lidia Alcalá; Ana Carballo-Castro; Ana Álvarez-Castro
Journal:  Insights Imaging       Date:  2016-04-30

8.  Variability and Reproducibility of 3rd-generation dual-source dynamic volume perfusion CT Parameters in Comparison to MR-perfusion Parameters in Rectal Cancer.

Authors:  Sonja Sudarski; Thomas Henzler; Teresa Floss; Tanja Gaa; Mathias Meyer; Holger Haubenreisser; Stefan O Schoenberg; Ulrike I Attenberger
Journal:  Sci Rep       Date:  2018-05-02       Impact factor: 4.379

9.  FDG-PET/CT in colorectal cancer: potential for vascular-metabolic imaging to provide markers of prognosis.

Authors:  Shih-Hsin Chen; Kenneth Miles; Stuart A Taylor; Balaji Ganeshan; Manuel Rodriquez; Francesco Fraioli; Simon Wan; Asim Afaq; Robert Shortman; Darren Walls; Luke Hoy; Raymond Endozo; Aman Bhargava; Matthew Hanson; Joseph Huang; Sherif Raouf; Daren Francis; Shahab Siddiqi; Tan Arulampalam; Bruce Sizer; Michael Machesney; Nicholas Reay-Jones; Sanjay Dindyal; Tony Ng; Ashley M Groves
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-04-10       Impact factor: 9.236

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.